Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma DOI Open Access

Su Min Cho,

Abdullah Esmail, Ali Raza

и другие.

Cancers, Год журнала: 2022, Номер 14(11), С. 2641 - 2641

Опубликована: Май 26, 2022

Cholangiocarcinoma (CCA) represents approximately 3% of gastrointestinal malignancies worldwide and constitutes around 10–15% all primary liver cancers, being only second to hepatocellular carcinoma. Mortality from CCA has been on the rise in recent decades, United States alone there a 36% increase 1999 2014, with over 7000 mortalities since 2013. Targeted therapies, which have gaining interest due their greater specificity toward cancer cells, recently started FDA approval for treatment CCA. In this manuscript, we will go through timeline current FDA-approved targeted therapies as well those that gained breakthrough therapy designation.

Язык: Английский

Role and Therapeutic Potential for Targeting Fibroblast Growth Factor 10/FGFR1 in Relapsed Rheumatoid Arthritis DOI Creative Commons

Xiaohui Meng,

Zechuan Chen, Teng Li

и другие.

Arthritis & Rheumatology, Год журнала: 2023, Номер 76(1), С. 32 - 47

Опубликована: Авг. 19, 2023

Fibroblast-like synoviocytes (FLSs) contribute to inflammation and joint damage in rheumatoid arthritis (RA). However, the regulatory mechanisms of FLSs relapse remission RA remain unknown. Identifying FLS heterogeneity their underlying pathogenic roles may lead discovering novel disease-modifying antirheumatic drugs.

Язык: Английский

Процитировано

15

MUC1 induces the accumulation of Foxp3+ Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway DOI
Guofeng Zhang,

Zheng Ge,

Haipeng Zhang

и другие.

International Immunopharmacology, Год журнала: 2023, Номер 118, С. 110091 - 110091

Опубликована: Апрель 3, 2023

Язык: Английский

Процитировано

14

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma DOI Creative Commons
Timothy P. DiPeri, Ming Zhao, Kurt W. Evans

и другие.

Journal of Hepatology, Год журнала: 2023, Номер 80(2), С. 322 - 334

Опубликована: Ноя. 14, 2023

Язык: Английский

Процитировано

14

FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis? DOI Creative Commons
Paulina Chmiel, Katarzyna Gęca, Karol Rawicz‐Pruszyński

и другие.

Cells, Год журнала: 2022, Номер 11(23), С. 3929 - 3929

Опубликована: Дек. 5, 2022

Cholangiocarcinomas (CCAs) are rare but aggressive tumours with poor diagnosis and limited treatment options. Molecular targeted therapies became a promising proposal for patients after progression under first-line chemical treatment. In light of an escalating prevalence CCA, it is crucial to fully comprehend its pathophysiology, aetiology, possible targets in therapy. Such knowledge would play pivotal role searching new therapeutic approaches concerning diseases’ symptoms their underlying causes. Growing evidence showed that fibroblast growth factor/fibroblast factor receptor (FGF/FGFR) pathway dysregulation involved variety processes during embryonic development homeostasis as well tumorigenesis. CCA known close correlation the FGF/FGFR targeting this axis has been proposed guidelines. Bearing mind significance molecular different neoplasms, seems most reasonable move towards intensive research testing on these case CCA. However, there still need more data covering topic. Although positive results many pre-clinical clinical studies discussed review, difficulties lie ahead. Furthermore, review presents up-to-date literature regarding outcomes latest discussion over future directions FGFR-directed

Язык: Английский

Процитировано

23

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma DOI Open Access

Su Min Cho,

Abdullah Esmail, Ali Raza

и другие.

Cancers, Год журнала: 2022, Номер 14(11), С. 2641 - 2641

Опубликована: Май 26, 2022

Cholangiocarcinoma (CCA) represents approximately 3% of gastrointestinal malignancies worldwide and constitutes around 10–15% all primary liver cancers, being only second to hepatocellular carcinoma. Mortality from CCA has been on the rise in recent decades, United States alone there a 36% increase 1999 2014, with over 7000 mortalities since 2013. Targeted therapies, which have gaining interest due their greater specificity toward cancer cells, recently started FDA approval for treatment CCA. In this manuscript, we will go through timeline current FDA-approved targeted therapies as well those that gained breakthrough therapy designation.

Язык: Английский

Процитировано

22